During the last session, Calidi Biotherapeutics Inc (AMEX:CLDI)’s traded shares were 1.54 million, with the beta value of the company hitting 1.04. At the end of the trading day, the stock’s price was $1.35, reflecting an intraday loss of -10.00% or -$0.15. The 52-week high for the CLDI share is $16.80, that puts it down -1144.44 from that peak though still a striking 57.04% gain since the share price plummeted to a 52-week low of $0.58. The company’s market capitalization is $34.98M, and the average trade volume was 2.25 million shares over the past three months.

Calidi Biotherapeutics Inc (AMEX:CLDI) trade information

Calidi Biotherapeutics Inc (CLDI) registered a -10.00% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -10.00% in intraday trading to $1.35, hitting a weekly high. The stock’s 5-day price performance is -8.78%, and it has moved by 52.40% in 30 days. Based on these gigs, the overall price performance for the year is -76.64%.

The consensus price target of analysts on Wall Street is $5.5, which implies an increase of 75.45% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $9 respectively. As a result, CLDI is trading at a discount of -566.67% off the target high and -48.15% off the low.

While earnings are projected to return 78.64% in 2025, the next five years will return 69.01% per annum.

CLDI Dividends

Calidi Biotherapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 0.56 million shares, is of CPR INVESTMENTS INC.’s that is approximately 1.0511% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.11 million.